Brian Haddigan: Beyond Stent Design – The Importance of Blood Compatibility
Brian Haddigan, Chief Executive Officer and Co Founder at Smart Reactors, shared a post on LinkedIn:
“What if the next breakthrough in venous stents isn’t the design, but the surface?
FDA post-market surveillance continues to receive reports of thrombosis, occlusion and restenosis associated with venous stents.
While these reports don’t measure complication rates, they reinforce that blood compatibility remains an important challenge.
Smart Reactors we’ve developed Camouflage, an ultra-thin, non-pharmacological hemocompatible coating designed to create a more blood-friendly surface, reducing platelet and fibrin adhesion while supporting natural healing.
The future of vascular implants includes solid engineering and smarter surfaces.
Could your next-generation device benefit from Camouflage?
Lets connect and find out..”
Stay updated with Hemostasis Today.
-
Jun 30, 2026, 04:47Kaihang Wang: Portal Vein Thrombosis After Pediatric Liver Transplantation
-
Jun 30, 2026, 04:12Maia Meier: Driving Change for Women and Girls with Bleeding Disorders
-
Jun 30, 2026, 03:19Wolfgang Miesbach: Weight-Bearing Lunge Test for Ankle Assessment in Haemophilia?
-
Jun 30, 2026, 03:06Salvatore Brugaletta: Is Twelve Months of DAPT Still Too Long After ACS?
-
Jun 30, 2026, 02:55Edward Lee Carter: How A Landmark Stewardship Shift Reduced Unnecessary Antiplatelet Use Across VISN 8
-
Jun 30, 2026, 02:43Nicolas Gendron: More than a Research Fellowship – Leaving the Wagner Lab
-
Jun 30, 2026, 02:29Wolfgang Miesbach: Can We ‘Pre‑Tame’ the Immune System to Unlock Better AAV8 FVIII Expression?
-
Jun 30, 2026, 02:21Mohammad Khalil: Evaluating DAPT Duration after Percutaneous Coronary Intervention
-
Jun 30, 2026, 02:11Rishdha Roshad: Activated Clotting Time – Adult vs Pediatric